Wellstat Therapeutics Corporation (Wellstat) is a privately held bio-pharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutics. Wellstat is focused on the development of therapeutics for patients in the fields of oncology, metabolic, neurodegenerative and neurometabolic diseases. The product pipeline of the company includes: PN401-cancer pancreatic, PN401-cancer gastric, PN4015-FU overdose, PN4015-neurometabolic, PN2034-diabetes, PN2034-gout, PN3000-nash and PN951-adult stem cell. Wellstat is part of the Wellstat Group of Companies (Washington, the US). The company has strong expertise in drug discovery, development, and commercialization. Recently, Wellstat and Sanofi-aventis announce that they entered into global licensing agreement to developing, manufacturing and commercializing PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes. The company is headquartered at Gaithersburg in Maryland, the US.